Uncovering the pathogenesis of large granular lymphocytic leukemia—novel STAT3 and STAT5b mutations

References

• Loughran TP Jr, Kadin ME, Starkebaum G, Abkowitz JL, Clark EA, Disteche C, et al. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med. 1985; 102:169–75.
   PubMed Web of Science ®Google Scholar
• Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood. 2011; 117:2764–74.
   PubMed Web of Science ®Google Scholar
• Mohan SR, Maciejewski JP. Diagnosis and therapy of neutropenia in large granular lymphocyte leukemia. Curr Opin Hematol. 2009;16: 27–34.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xu X, Liu Y. Activation-induced cell death in T cells and autoimmunity. Cell Mol Immunol. 2004;1:186–92.
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107:351–62.
   PubMed Web of Science ®Google Scholar
• Yang J, Epling-Burnette PK, Painter JS, Zou J, Bai F, Wei S, et al. Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia. Blood. 2008;111:1610–16.
   PubMed Web of Science ®Google Scholar
• Leblanc F, Zhang D, Liu X, Loughran TP. Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets. Future Oncol. 2012;8:787–801.
   PubMed Web of Science ®Google Scholar
• Zhang R, Shah MV, Yang J, Nyland SB, Liu X, Yun JK, et al. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci U S A. 2008;105:16308–13.
   PubMed Web of Science ®Google Scholar
• Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366:1905–13.
   PubMed Web of Science ®Google Scholar
• Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120:3048–57.
   PubMed Web of Science ®Google Scholar
• Lim CP, Cao X. Structure, function, and regulation of STAT proteins. Mol Biosyst. 2006;2:536–50.
   PubMedGoogle Scholar
• Maritano D, Sugrue ML, Tininini S, Dewilde S, Strobl B, Fu X, et al. The STAT3 isoforms alpha and beta have unique and specific functions. Nat Immunol. 2004;5:401–9.
   PubMed Web of Science ®Google Scholar
• Ambrosio R, Fimiani G, Monfregola J, Sanzari E, De Felice N, Salerno MC, et al. The structure of human STAT5A and B genes reveals two regions of nearly identical sequence and an alternative tissue specific STAT5B promoter. Gene. 2002;285:311–18.
   PubMed Web of Science ®Google Scholar
• Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334(Pt 2):297–314.
   PubMedGoogle Scholar
• Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000;19:2548–56.
   PubMed Web of Science ®Google Scholar
• Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000;19:2468–73.
   PubMed Web of Science ®Google Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798–809.
   PubMed Web of Science ®Google Scholar
• Wen Z, Darnell JE Jr. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res. 1997;25:2062–7.
   PubMed Web of Science ®Google Scholar
• Kang K, Robinson GW, Hennighausen L. Comprehensive meta-analysis of Signal Transducers and Activators of Transcription (STAT) genomic binding patterns discerns cell-specific cis-regulatory modules. BMC Genomics. 2013;14:4.
   PubMed Web of Science ®Google Scholar
• Greenhalgh CJ, Hilton DJ. Negative regulation of cytokine signaling. J Leukoc Biol. 2001;70:348–56.
   PubMed Web of Science ®Google Scholar
• Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A. 1997;94:3801–4.
   PubMed Web of Science ®Google Scholar
• Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, Akira S. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol. 1998;161:4652–60.
   PubMed Web of Science ®Google Scholar
• Akaishi H, Takeda K, Kaisho T, Shineha R, Satomi S, Takeda J, et al. Defective IL-2-mediated IL-2 receptor alpha chain expression in Stat3-deficient T lymphocytes. Int Immunol. 1998;10:1747–51.
   PubMed Web of Science ®Google Scholar
• Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007;357:1608–19.
   PubMed Web of Science ®Google Scholar
• Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007;448:1058–62.
   PubMed Web of Science ®Google Scholar
• Yu H, Jove R. The STATs of cancer—new molecular targets come of age. Nat Rev Cancer. 2004;4:97–105.
   PubMed Web of Science ®Google Scholar
• Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene. 2000;19:2489–95.
   PubMed Web of Science ®Google Scholar
• Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth In vitro. J Clin Invest. 1998;102:1385–92.
   PubMed Web of Science ®Google Scholar
• Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10: 105–15.
   PubMed Web of Science ®Google Scholar
• Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 2001;20:2499–513.
   PubMed Web of Science ®Google Scholar
• Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002;8:945–54.
   PubMed Web of Science ®Google Scholar
• Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B, Behrmann I, et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood. 2001;98:762–70.
   PubMed Web of Science ®Google Scholar
• Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333:1154–7.
   PubMed Web of Science ®Google Scholar
• Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471:467–72.
   PubMed Web of Science ®Google Scholar
• Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell. 1999;98:295–303.
   PubMed Web of Science ®Google Scholar
• Harris TJ, Grosso JF, Yen HR, Xin H, Kortylewski M, Albesiano E, et al. Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol. 2007; 179:4313–17.
   PubMed Web of Science ®Google Scholar
• Gaston JS. Cytokines in arthritis—the ‘big numbers’ move centre stage. Rheumatology (Oxford). 2008;47:8–12.
   PubMed Web of Science ®Google Scholar
• Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007;9:461–7.
   PubMedGoogle Scholar
• Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13:1173–5.
   PubMed Web of Science ®Google Scholar
• Schmechel S, Konrad A, Diegelmann J, Glas J, Wetzke M, Paschos E, et al. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis. 2008;14:204–12.
   PubMed Web of Science ®Google Scholar
• Fasan A, Kern W, Grossmann V, Haferlach C, Haferlach T, Schnittger S. STAT3 mutations are highly specific for large granular lymphocytic leukemia. Leukemia. 2013;27:1598–600.
   PubMed Web of Science ®Google Scholar
• Ohgami RS, Ma L, Merker JD, Martinez B, Zehnder JL, Arber DA. STAT3 mutations are frequent in CD30 + T-cell lymphomas and T-cell large granular lymphocytic leukemia. Leukemia. 2013;27:2244–7.
   PubMed Web of Science ®Google Scholar
• Rajala HL, Eldfors S, Kuusanmaki H, Andersson EI, van Adrichem AJ, Lagstrom S, et al. Deep sequencing reveals small subclones of STAT3 mutations in large granular lymphocytic leukemia. European Hematology Association, 18th Congress of EHA, June 13–16, 2013, Stockholm, Sweden.
   Google Scholar
• Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, Paradis V, et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med. 2011;208:1359–66.
   PubMed Web of Science ®Google Scholar
• Couronne L, Scourzic L, Pilati C, Valle VD, Duffourd Y, Solary E, et al. STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica. 2013;98:1748–52.
   PubMed Web of Science ®Google Scholar
• Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature. 2009;457:200–4.
   PubMed Web of Science ®Google Scholar
• Hu G, Witzig TE, Gupta M. A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling. PLoS One. 2013;8:e67851.
   Web of Science ®Google Scholar
• Kim MS, Lee SH, Yoo NJ, Lee SH. STAT3 exon 21 mutation is rare in common human cancers. Acta Oncol. 2013;52:1221–2.
   PubMed Web of Science ®Google Scholar
• Young NS. Acquired aplastic anemia. Ann Intern Med. 2002;136: 534–46.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361:1872–85.
   PubMed Web of Science ®Google Scholar
• Karadimitris A, Li K, Notaro R, Araten DJ, Nafa K, Thertulien R, et al. Association of clonal T-cell large granular lymphocyte disease and paroxysmal nocturnal haemoglobinuria (PNH): further evidence for a pathogenetic link between T cells, aplastic anaemia and PNH. Br J Haematol. 2001;115:1010–14.
   PubMed Web of Science ®Google Scholar
• Jerez A, Clemente MJ, Makishima H, Rajala H, Gomez-Segui I, Olson T, et al. STAT3-mutations indicate the presence of subclinical T cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013;122:2453–9.
   PubMed Web of Science ®Google Scholar
• Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A. 1997;94: 7239–44.
   PubMed Web of Science ®Google Scholar
• Imada K, Bloom ET, Nakajima H, Horvath-Arcidiacono JA, Udy GB, Davey HW, et al. Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med. 1998;188:2067–74.
   PubMed Web of Science ®Google Scholar
• Eckelhart E, Warsch W, Zebedin E, Simma O, Stoiber D, Kolbe T, et al. A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood. 2011;117:1565–73.
   PubMed Web of Science ®Google Scholar
• Hwa V, Camacho-Hubner C, Little BM, David A, Metherell LA, El-Khatib N, et al. Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene. Horm Res. 2007;68:218–24.
   PubMedGoogle Scholar
• Kanai T, Jenks J, Nadeau KC. The STAT5b pathway defect and autoimmunity. Front Immunol. 2012;3:234.
   PubMed Web of Science ®Google Scholar
• Yao Z, Cui Y, Watford WT, Bream JH, Yamaoka K, Hissong BD, et al. Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci U S A. 2006;103:1000–5.
   PubMed Web of Science ®Google Scholar
• Fabbro D. BCR-ABL signaling: a new STATus in CML. Nat Chem Biol. 2012;8:228–9.
   PubMed Web of Science ®Google Scholar
• Rajala HL, Mustjoki S. STAT5b in LGL leukemia - a novel therapeutic target?. Oncotarget. 2013;4:808–9.
   PubMed Web of Science ®Google Scholar
• Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood. 2000;96:2269–76.
   PubMed Web of Science ®Google Scholar
• Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996;13:247–54.
   PubMed Web of Science ®Google Scholar
• Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011; 117:3421–9.
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013;32:2601–13.
   PubMed Web of Science ®Google Scholar
• Funakoshi-Tago M, Tago K, Abe M, Sonoda Y, Kasahara T. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. J Biol Chem. 2010; 285:5296–307.
   PubMed Web of Science ®Google Scholar
• Onishi M, Nosaka T, Misawa K, Mui AL, Gorman D, McMahon M, et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol. 1998;18:3871–9.
   PubMed Web of Science ®Google Scholar
• Ariyoshi K, Nosaka T, Yamada K, Onishi M, Oka Y, Miyajima A, et al. Constitutive activation of STAT5 by a point mutation in the SH2 domain. J Biol Chem. 2000;275:24407–13.
   PubMed Web of Science ®Google Scholar
• Yamada K, Ariyoshi K, Onishi M, Miyajima A, Hayakawa F, Towatari M, et al. Constitutively active STAT5A and STAT5B in vitro and in vivo: mutation of STAT5 is not a frequent cause of leukemogenesis. Int J Hematol. 2000;71:46–54.
   PubMed Web of Science ®Google Scholar
• Rajala HL, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, Lagstrom S, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013;121:4541–50.
   PubMed Web of Science ®Google Scholar
• Andersson EI, Rajala HL, Eldfors S, Ellonen P, Olson T, Jerez A, et al. Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. Blood Cancer J. 2013;3:e168.
   Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19.
   PubMed Web of Science ®Google Scholar
• Saha A, Robertson ES. Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes. Clin Cancer Res. 2011;17: 3056–63.
   PubMed Web of Science ®Google Scholar
• Hart DN, Baker BW, Inglis MJ, Nimmo JC, Starling GC, Deacon E, et al. Epstein-Barr viral DNA in acute large granular lymphocyte (natural killer) leukemic cells. Blood. 1992;79:2116–23.
   PubMed Web of Science ®Google Scholar
• Coppo P, Gouilleux-Gruart V, Huang Y, Bouhlal H, Bouamar H, Bouchet S, et al. STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma. Leukemia. 2009;23:1667–78.
   PubMed Web of Science ®Google Scholar
• Shukla S, Shishodia G, Mahata S, Hedau S, Pandey A, Bhambhani S, et al. Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection. Mol Cancer. 2010;9:282.
   PubMed Web of Science ®Google Scholar
• Thomas A, Perzova R, Abbott L, Benz P, Poiesz MJ, Dube S, et al. LGL leukemia and HTLV. AIDS Res Hum Retroviruses. 2010;26:33–40.
   PubMed Web of Science ®Google Scholar
• O’Keefe CL, Plasilova M, Wlodarski M, Risitano AM, Rodriguez AR, Howe E, et al. Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responses. J Immunol. 2004;172:1960–9.
   PubMed Web of Science ®Google Scholar
• Rajala HL, Eldfors S, Kuusanmaki H, Andersson EI, van Adrichem AJ, Lagstrom S, et al. Discovery of STAT5b mutations and small subclones of STAT3 mutations in large granular lymphocytic (LGL) leukemia. Blood (ASH Annual Meeting Abstracts). 2012;120(Abstract 871).
   Google Scholar
• Mishra A, Liu S, Sams GH, Curphey DP, Santhanam R, Rush LJ, et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell. 2012;22:645–55.
   PubMed Web of Science ®Google Scholar
• Ohkawa T, Seki S, Dobashi H, Koike Y, Habu Y, Ami K, et al. Systematic characterization of human CD8 + T cells with natural killer cell markers in comparison with natural killer cells and normal CD8 + T cells. Immunology. 2001;103:281–90.
   PubMed Web of Science ®Google Scholar
• Langerak AW, Groenen PJ, Bruggemann M, Beldjord K, Bellan C, Bonello L, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia. 2012;26:2159–71.
   PubMed Web of Science ®Google Scholar
• Langerak AW, van Den Beemd R, Wolvers-Tettero IL, Boor PP, van Lochem EG, Hooijkaas H, et al. Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations. Blood. 2001;98:165–73.
   PubMed Web of Science ®Google Scholar
• Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116:772–82.
   PubMed Web of Science ®Google Scholar
• Gillespie GM, Wills MR, Appay V, O’Callaghan C, Murphy M, Smith N, et al. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol. 2000;74:8140–50.
   PubMed Web of Science ®Google Scholar
• Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23:1398–405.
   PubMed Web of Science ®Google Scholar
• Posnett DN, Sinha R, Kabak S, Russo C. Clonal populations of T cells in normal elderly humans: the T cell equivalent to “benign monoclonal gammapathy”. J Exp Med. 1994;179:609–18.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A. 2012;109:9623–8.
   PubMed Web of Science ®Google Scholar
• Hayakawa F, Sugimoto K, Kurahashi S, Sumida T, Naoe T. A novel STAT3 inhibitor OPB-31121 induces tumor-specific growth inhibition in a wide range of hematopoietic malignancies without growth suppression of normal hematopoietic cells. Blood (ASH Annual Meeting Abstracts). 2011;118(Abstract 577).
   Google Scholar
• Souissi I, Najjar I, Ah-Koon L, Schischmanoff PO, Lesage D, Le Coquil S, et al. A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-kappaB. BMC Cell Biol. 2011;12:14.
   PubMedGoogle Scholar
• Page BD, Khoury H, Laister RC, Fletcher S, Vellozo M, Manzoli A, et al. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. J Med Chem. 2012;55:1047–55.
   PubMed Web of Science ®Google Scholar
• Miklossy G, Hilliard TS, Turkson J. Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov. 2013;12:611–29.
   PubMed Web of Science ®Google Scholar
• Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, Barrett R, et al. The STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous leukemia driven by FLT3 mutations. Genes Cancer. 2012;3:503–11.
   PubMedGoogle Scholar
• Epling-Burnette PK, Catlett-Falcone R, Kothapalli R, Oshiro M, Jove R, Loughran TP. Induction of apoptosis in large granular lymphocyte (Lgl) leukemia by jak tyrosine kinase inhibitor AG-490: role of STAT3-regulated MCL-1. ISEH Annual Meeting: Experimental Hematology. 2000;28:90–1.
   Web of Science ®Google Scholar